Cenigaonandia-Campillo et al. (134) found that higher doses of VC (5–10 mM) inhibited KRAS mutant colon cancer growth in both in vivo and in vitro studies by reducing mitochondrial membrane potential and levels of ATP and GLUT1 in cancer cells. The gene discussed is SLC2A1; the disease is cancer.